Every DEF 14A that VICARIOUS SRGCL INC A (RBOT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RBOT filings page.
Vicarious Surgical Inc. is asking stockholders to approve an assignment for the benefit of creditors followed by a complete dissolution under a Plan of Dissolution. The company states that, based on its current liabilities, it is unlikely common stockholders will receive any cash distribution.
As of March 31, 2026, Vicarious Surgical reported total assets of $12.586 million, total liabilities of $9.016 million, and cash, cash equivalents and short-term investments of $3.682 million, which it does not expect to support it as a going concern for long. The board reports unsuccessful efforts to secure additional financing or a buyer and believes an assignment for the benefit of creditors plus dissolution offers a better recovery path for creditors than bankruptcy, with only a remote chance of residual value for equity holders.
Vicarious Surgical Inc. is asking stockholders to approve a reverse stock split of its Class A and Class B common stock, at a ratio between 1‑for‑2 and 1‑for‑30, with the exact ratio and timing to be set later by the board of directors or abandoned entirely.
The main goal is to raise the per‑share price of Class A stock to help qualify for an uplisting to the Nasdaq Capital Market after the New York Stock Exchange suspended trading and began delisting proceedings for failing to meet its $15 million market capitalization standard. The company’s Class A shares now trade on the OTC Markets under the symbol “RBOT.”
The proxy explains that a reverse split would reduce outstanding shares, proportionately adjust options, warrants and other equity awards, and pay cash instead of issuing fractional shares. It also notes potential risks, including no guarantee of a higher or sustained share price and possible lower trading liquidity, while authorized share counts would remain unchanged, increasing the number of shares available for future issuance.
Vicarious Surgical Inc. has called a special stockholder meeting on January 9, 2026 to vote on allowing the exercise of Common Warrants issued on October 7, 2025. These warrants give an institutional investor the right to buy up to 2,300,000 shares of Class A common stock at an exercise price of $5.10 per share, but they are not exercisable until stockholders approve their exercise under New York Stock Exchange rules.
The company previously raised about $5.9 million in gross proceeds in an October 2025 registered direct offering and concurrent private placement. As of September 30, 2025, it held roughly $3.2 million in cash and $10.3 million in short‑term investments. If the proposal is approved and all warrants are exercised for cash, Vicarious Surgical could receive up to approximately $11.7 million in additional gross proceeds, while existing holders would face dilution as up to 2,300,000 new shares become issuable. The board of directors unanimously recommends voting “FOR” the proposal.